Tvardi Therapeutics, Inc.
TVRD evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $17.7M
- Lead Asset:
- tti-101 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for TVRD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TVRD
Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company developing oral small-molecule STAT3 inhibitors for inflammatory and proliferative diseases, with lead candidates TTI-101 and TTI-109.
Key risk: Funding dependency
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 2 catalysts for Tvardi Therapeutics, Inc..
Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company developing oral small-molecule STAT3 inhibitors for inflammatory and proliferative diseases, with lead candidates TTI-101 and TTI-109.
- Cash & equivalents of $15.8M as of 2026-06-30 [sec].
- Net income of -$6.5M as of 2026-06-30 [sec].
- Shareholders' equity of $8.4M as of 2026-06-30 [sec].
- Phase 2 topline data for TTI-101 in hepatocellular carcinoma (HCC) anticipated in H2 2026 [news · 2026-03-31].
- Healthy volunteer study results for TTI-109 on track for Q2 2026 [news · 2026-03-31].
What works
- Pipeline includes two oral STAT3 inhibitors (TTI-101 and TTI-109) targeting a historically undruggable target [sec_mda · as of 2026-08-14].
- Interim Phase 2 data for TTI-101 in HCC showed clinically meaningful activity as monotherapy and in combination [news · 2026-03-31].
- Cash runway expected to fund operations through clinical readouts and into Q4 2026 [news · 2026-05-08].
What to weigh
- Company will require additional funding to finance operations and complete ongoing/planned trials; access to such funding on acceptable terms cannot be assured [sec_mda · as of 2026-08-14].
- Net loss of $6.5M reported as of 2026-06-30 [sec].
- Phase 2 topline readout for TTI-101 in HCC was delayed to H2 2026 to allow data maturation [news · 2026-03-31].
From the filings
Quoted directly from source documents.
Company focus on STAT3 inhibition
“clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need”
SEC MD&A · August 14, 2026
Cash runway through Q4 2026
“Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026”
News · May 8, 2026
Phase 2 HCC data readout timing
“Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026”
News · March 31, 2026
Need for additional funding
“We will require additional funding in order to finance operations and complete our ongoing and planned clinical trials. Access to such funding on acceptable terms cannot be assured.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline — Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
- 2026-12-31 · Phase2_Topline — Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Risks & what to watch (3)›
Key risks
- Funding dependency — Company will require additional funding to complete trials; access on acceptable terms not assured [sec_mda · as of 2026-08-14].
- Clinical data delay
- Net loss position — Net loss of $6.5M as of 2026-06-30 [sec].
What to watch
- Topline Phase 2 data for TTI-101 in HCC expected H2 2026 [news · 2026-03-31].
- Healthy volunteer study results for TTI-109 expected Q2 2026 [news · 2026-03-31].
- Cash runway sufficiency through Q4 2026 and subsequent financing needs [news · 2026-05-08].
Sources: Catalysts · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Tvardi Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tvardi Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.09 · 0% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~79d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
67
Total value held
$8.6M
| Holder | Shares | Value |
|---|---|---|
| slate path capital lp | 704,118 | $2.2M |
| blackrock, inc. | 388,075 | $1.2M |
| vanguard capital management llc | 344,708 | $1.1M |
| american financial group inc | 223,659 | $711K |
| geode capital management, llc | 182,339 | $580K |
| silvercrest asset management group llc | 101,034 | $321K |
| state street corp | 97,231 | $309K |
| renaissance technologies llc | 92,100 | $293K |
| morgan stanley | 72,894 | $232K |
| duncan williams asset management, llc | 63,241 | $201K |
Showing top 10 of 67 institutional holders of Tvardi Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 5.5%
- Days to cover
- 9.9
- Shares short
- 508,941
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TVRD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tvardi Therapeutics, Inc.?
Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company developing oral small-molecule STAT3 inhibitors for inflammatory and proliferative diseases, with lead candidates TTI-101 and TTI-109.
What is Tvardi Therapeutics, Inc.'s lead drug candidate?
Tvardi Therapeutics, Inc.'s most advanced tracked candidate is tti-101 (Phase 2) for Breast Cancer; Hepatocellular Carcinoma; Idiopathic Pulmonary Fibrosis.
What is Tvardi Therapeutics, Inc.'s next catalyst?
Tvardi Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update" — expected December 31, 2026.
Who is the CEO of Tvardi Therapeutics, Inc.?
Dr. Imran Alibhai Ph.D. is the chief executive officer of Tvardi Therapeutics, Inc. (TVRD).
Where is Tvardi Therapeutics, Inc. headquartered?
Tvardi Therapeutics, Inc. (TVRD) is headquartered in Sugar Land, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.